Where I see patients (1)
Selected research
-
Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer.
Cancer immunology research
-
RPL22 is a tumor suppressor in MSI-high cancers and a key splicing regulator of MDM4.
bioRxiv : the preprint server for biology
-
Single-nuclei characterization of pervasive transcriptional signatures across organs in response to COVID-19.
eLife
Contact me
- Request appointment
- Refer a patient
- (415) 476-4616